Compare Adaptive Biotechnologies Corp (ADPT) vs Snowflake Inc (SNOW) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Adaptive Biotechnologies Corp vs Snowflake Inc — how do they compare? Adaptive Biotechnologies Corp trades at $25.16 (market cap $4.04B), while Snowflake Inc trades at $338.96 (market cap $116.01B). The key difference: Snowflake Inc is far larger — about 28.7× Adaptive Biotechnologies Corp's market cap. Which is the better fit depends on your goals.
| ADPT | SNOW | |
|---|---|---|
Market Cap | $4.04B | $116.01B |
Sector | Health | Technology |
52-Week High | $25.45 | $334.70 |
52-Week Low | $12.30 | $121.11 |
Enterprise Value | $4.10B | $115.82B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ADPT trades at $25.45, up 2.09% today, near its 52-week high. The stock shows bullish technical signals with support at $25 and resistance at $26. Revenue growth accelerated to $277M in 2025, though net losses persist. Recent news highlights a strategic separation of its MRD and Immune Medicine businesses, aiming to unlock value.
Outlook is cautiously optimistic with 65% analyst buy ratings and a $25.50 price target. Key opportunities include MRD segment profitability and separation benefits, while risks involve sustained losses, competitive pressures, and execution challenges in the business split.
Snowflake (SNOW) trades at $334.7, up 1.27% on the day, reflecting strong momentum amid a bullish technical signal. The stock has consistently beaten earnings estimates in recent quarters, with Q1 2026 EPS of $0.39 exceeding expectations. Revenue growth remains robust, reaching $3.63 billion in 2025, though profitability challenges persist with a net income margin of -23.79%. Recent news highlights product innovations, including AI integrations and security enhancements, driving investor optimism.
Outlook is supported by Wall Street's bullish consensus, with 81% of analysts rating SNOW a buy and a price target of $302.18. However, high valuation multiples, intense competition, and ongoing losses present significant risks. The stock's proximity to its 52-week high suggests limited near-term upside without further positive catalysts.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Adaptive Biotechnologies Corp
Adaptive Biotechnologies Corp is a commercial-stage company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease in patients with select blood cancers.
Read more on ADPT →About Snowflake Inc
Founded in 2012, Snowflake is a data lake, warehousing, and sharing company that came public in 2020. To date, the company has over 3,000 customers including nearly 30% of the Fortune 500 as its customers. Snowflake's data lake stores unstructured and semistructured data that can then be used in analytics to create insights stored in its data warehouse. Snowflake's data sharing capability allows enterprises to easily buy and ingest data almost instantaneously compared with a traditionally months-long process. Overall, the company is known for the fact that all of its data solutions that can be hosted on various public clouds.
Read more on SNOW →
